DexCom (NASDAQ:DXCM) Trading 10.7% Higher on Earnings Beat

Shares of DexCom, Inc. (NASDAQ:DXCM) traded up 10.7% on Friday following a stronger than expected earnings report. The stock traded as high as $83.49 and last traded at $82.5430. Approximately 2,178,992 shares changed hands during mid-day trading, a decline of 58% from the average session volume of 5,193,135 shares. The stock had previously closed at $74.54.

The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. During the same quarter in the prior year, the company posted $0.48 EPS. The business’s revenue was up 13.1% on a year-over-year basis.

Key Headlines Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom exceeded second-quarter expectations, reporting adjusted EPS of $0.70 versus the $0.61 consensus estimate and revenue of $1.31 billion versus $1.29 billion expected. Revenue increased 13% year over year, while EPS rose from $0.48 a year earlier. Reuters article
• Positive Sentiment: The company raised its 2026 revenue outlook to approximately $5.18 billion-$5.25 billion, supported by sustained demand for continuous glucose monitoring devices. Management is targeting nearly 50% U.S. adoption of the G7 15-Day sensor by year-end. Seeking Alpha outlook article
• Positive Sentiment: Worldwide revenue growth included $933 million from the U.S., up 11%, with international sales also contributing to the overall 12% organic growth rate. The raised forecast and quarterly beat initially sent shares higher in extended trading. GuruFocus earnings highlights
• Positive Sentiment: UBS reaffirmed its Buy rating and maintained a $96 price target, implying substantial upside from the referenced share price. Benzinga analyst coverage
• Neutral Sentiment: Although the earnings news is favorable, the subsequent pullback may reflect profit-taking after the initial rally or investor caution about expectations at a valuation near 32 times earnings.
• Negative Sentiment: Medical-device companies continue to face potential margin pressure from tariffs and inflation, risks that could temper the benefit of strong underlying demand. Zacks medical-product outlook

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Raymond James Financial reiterated a “strong-buy” rating on shares of DexCom in a research note on Friday. BTIG Research reaffirmed a “buy” rating and issued a $90.00 price target (up from $80.00) on shares of DexCom in a research note on Friday. UBS Group set a $96.00 price target on DexCom and gave the company a “buy” rating in a research note on Tuesday. William Blair upgraded DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Finally, Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $86.92.

Insider Activity

In other news, Director Mark G. Foletta sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $74.13, for a total transaction of $296,520.00. Following the completion of the sale, the director owned 52,852 shares of the company’s stock, valued at approximately $3,917,918.76. This trade represents a 7.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total transaction of $60,730.12. Following the completion of the transaction, the director owned 25,007 shares of the company’s stock, valued at $1,500,670.07. This trade represents a 3.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 98,506 shares of company stock valued at $7,205,258. Corporate insiders own 0.28% of the company’s stock.

Institutional Investors Weigh In On DexCom

A number of hedge funds and other institutional investors have recently bought and sold shares of DXCM. Reflection Asset Management bought a new position in DexCom in the 4th quarter valued at $25,000. Ascentis Independent Advisors bought a new stake in shares of DexCom during the first quarter worth $25,000. MCF Advisors LLC bought a new stake in shares of DexCom during the fourth quarter worth $32,000. ORG Partners LLC increased its stake in shares of DexCom by 124.3% in the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after buying an additional 281 shares in the last quarter. Finally, Wellington Grp LLC increased its stake in shares of DexCom by 778.7% in the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after buying an additional 475 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Price Performance

The stock has a fifty day moving average of $72.91 and a 200-day moving average of $69.10. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $31.57 billion, a P/E ratio of 35.25, a PEG ratio of 1.24 and a beta of 1.45.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.